Neuren Pharmaceuticals Receives First Milestone Payment for Rett Syndrome Drug; Shares Down 6%

MT Newswires Live

2025/02/28

Neuren Pharmaceuticals (ASX:NEU) received its first sales milestone payment of $50 million for the first year that the net sales of Rett syndrome drug Daybue exceeded $250 million in North America, according to a Friday filing with the Australian bourse.

The company's Nasdaq-listed partner Acadia Pharmaceuticals reported $348.4 million net sales of the drug in the US in 2024, the filing said.

The company will receive the second milestone payment from commercialization of the drug when net sales exceed $500 million, according to the filing.

Neuren Pharmaceuticals shares fell 6% in afternoon trade Friday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2514024361"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514024361\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2514024361?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-28 10:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514024361","market":"hk","top_or_hot":-1,"title":"Neuren Pharmaceuticals Receives First Milestone Payment for Rett Syndrome Drug; Shares Down 6%","media":"MT Newswires Live","content":"<html><body><p> Neuren Pharmaceuticals (ASX:NEU) received its first sales milestone payment of $50 million for the first year that the net sales of Rett syndrome drug Daybue exceeded $250 million in North America, according to a Friday filing with the Australian bourse.</p><p>The company's Nasdaq-listed partner Acadia Pharmaceuticals reported $348.4 million net sales of the drug in the US in 2024, the filing said.</p><p>The company will receive the second milestone payment from commercialization of the drug when net sales exceed $500 million, according to the filing.</p><p>Neuren Pharmaceuticals shares fell 6% in afternoon trade Friday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neuren Pharmaceuticals Receives First Milestone Payment for Rett Syndrome Drug; Shares Down 6%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuren Pharmaceuticals Receives First Milestone Payment for Rett Syndrome Drug; Shares Down 6%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-28 10:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Neuren Pharmaceuticals (ASX:NEU) received its first sales milestone payment of $50 million for the first year that the net sales of Rett syndrome drug Daybue exceeded $250 million in North America, according to a Friday filing with the Australian bourse.</p><p>The company's Nasdaq-listed partner Acadia Pharmaceuticals reported $348.4 million net sales of the drug in the US in 2024, the filing said.</p><p>The company will receive the second milestone payment from commercialization of the drug when net sales exceed $500 million, according to the filing.</p><p>Neuren Pharmaceuticals shares fell 6% in afternoon trade Friday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2514024361","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514024361","pubTimestamp":1740709061,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Neuren Pharmaceuticals  received its first sales milestone payment of $50 million for the first year that the net sales of Rett syndrome drug Daybue exceeded $250 million in North America, according to a Friday filing with the Australian bourse.The company's Nasdaq-listed partner Acadia Pharmaceuticals reported $348.4 million net sales of the drug in the US in 2024, the filing said.The company will receive the second milestone payment from commercialization of the drug when net sales exceed $500 million, according to the filing.Neuren Pharmaceuticals shares fell 6% in afternoon trade Friday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","NEU.AU":"NEUREN PHARMACEUTICALS LTD","BK7096":"制药"},"translate_title":"Neuren Pharmaceuticals收到Rett综合征药物的第一笔里程碑付款；股价下跌6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEU.AU":0.9},"content_text":"Neuren Pharmaceuticals (ASX:NEU) received its first sales milestone payment of $50 million for the first year that the net sales of Rett syndrome drug Daybue exceeded $250 million in North America, according to a Friday filing with the Australian bourse.The company's Nasdaq-listed partner Acadia Pharmaceuticals reported $348.4 million net sales of the drug in the US in 2024, the filing said.The company will receive the second milestone payment from commercialization of the drug when net sales exceed $500 million, according to the filing.Neuren Pharmaceuticals shares fell 6% in afternoon trade Friday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}